These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30423862)

  • 1. Radiobiological Characterization of
    Guerreiro JF; Alves V; Abrunhosa AJ; Paulo A; Gil OM; Mendes F
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423862
    [No Abstract]   [Full Text] [Related]  

  • 2. 64CuCl2 PET/CT as a potential new imaging method in prostate cancer: illusion or reality?
    Cantiello F; Crocerossa F; Cascini GL; Russo GI; Ferro M; Cimino S; Lucarelli G; Damiano R
    Minerva Urol Nephrol; 2021 Oct; 73(5):668-671. PubMed ID: 32182228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
    Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
    Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of DNA damage and p21-dependent senescence by Riccardin D is a novel mechanism contributing to its growth suppression in prostate cancer cells in vitro and in vivo.
    Hu Z; Zhang D; Hao J; Tian K; Wang W; Lou H; Yuan H
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):397-407. PubMed ID: 24322375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
    Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
    Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer.
    Xiang J; Bian C; Wang H; Huang S; Wu D
    J Exp Clin Cancer Res; 2015 Jan; 34(1):8. PubMed ID: 25636908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133(+) cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite.
    Yoshii Y; Furukawa T; Matsumoto H; Yoshimoto M; Kiyono Y; Zhang MR; Fujibayashi Y; Saga T
    Cancer Lett; 2016 Jun; 376(1):74-82. PubMed ID: 26996296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copper-64 Chloride Exhibits Therapeutic Potential in Three-Dimensional Cellular Models of Prostate Cancer.
    Pinto CIG; Bucar S; Alves V; Fonseca A; Abrunhosa AJ; da Silva CL; Guerreiro JF; Mendes F
    Front Mol Biosci; 2020; 7():609172. PubMed ID: 33335914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells.
    Kong Z; Raghavan P; Xie D; Boike T; Burma S; Chen D; Chakraborty A; Hsieh JT; Saha D
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1210-8. PubMed ID: 20970033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biological functions and mechanism of miR‑212 in prostate cancer proliferation, migration and invasion via targeting Engrailed-2.
    Zhou Y; Ji Z; Yan W; Zhou Z; Li H
    Oncol Rep; 2017 Sep; 38(3):1411-1419. PubMed ID: 28713997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model.
    Kim KI; Jang SJ; Park JH; Lee YJ; Lee TS; Woo KS; Park H; Choe JG; An GI; Kang JH
    J Nucl Med; 2014 Oct; 55(10):1692-8. PubMed ID: 25091475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis.
    Lee E; Wang J; Yumoto K; Jung Y; Cackowski FC; Decker AM; Li Y; Franceschi RT; Pienta KJ; Taichman RS
    Neoplasia; 2016 Sep; 18(9):553-66. PubMed ID: 27659015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
    Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
    Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSMA ligands in prostate cancer - Probe optimization and theranostic applications.
    Lütje S; Slavik R; Fendler W; Herrmann K; Eiber M
    Methods; 2017 Nov; 130():42-50. PubMed ID: 28666778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of OATP transporters in steroid uptake by prostate cancer cells in vivo.
    Green SM; Kaipainen A; Bullock K; Zhang A; Lucas JM; Matson C; Banks WA; Mostaghel EA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):20-27. PubMed ID: 27645128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
    Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
    Angelucci A; Gravina GL; Rucci N; Millimaggi D; Festuccia C; Muzi P; Teti A; Vicentini C; Bologna M
    Endocr Relat Cancer; 2006 Mar; 13(1):197-210. PubMed ID: 16601288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.